Covaxin overall 77.8% effective, Bharat Biotech claims in Phase 3 data

New Delhi : Bharat Biotech’s Covaxin is overall 77.8% effective against coronavirus, the vaccine makers said in a statement, citing clinical data from the third phase trials.

The vaccine is 66.2% effective on the Delta variant, which was among the prime reasons behind the second wave of coronavirus in India.

It was also found to be "93.4 per cent effective" against severe symptomatic COVID-19, the company said.

Covaxin is a whole virus inactivated vaccine developed jointly by ICMR and NIV Pune.

The Phase 3 clinical trial was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India.

"We are proud to put India on the global map with scientific conviction, competence and commitment. Covaxin scores 10 world-class publications endorsing Innovation, clinical research, data, safety, efficacy. Thank collaborators & Positive BB teamwork enduring a pandemic (sic)," Bharat Biotech co-founder Suchitra Ella said in a late-night tweet.

In a statement, the vaccine maker further said, "Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group."

(Image)